Pakistan journal of pharmaceutical sciences · 2026
Comparative efficacy of doxophylline-ambroxol combination versus aminophylline in the management of acute exacerbations of COPD: A retrospective case-control study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Chendong, Zhou Gangwei, Wan Si, Jiang Jiaru, Shen Fei, Jiang Sicong, Zhu Qunchao
Аннотация
BACKGROUND: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) manifests as sudden respiratory symptom aggravation and airflow decline, substantially elevating mortality risk, making therapeutic optimization crucial for patient outcomes.
OBJECTIVES: To compare the clinical efficacy and safety of the combination therapy of Doxophylline ambroxol and Aminophylline monotherapy in the treatment of AECOPD.
METHODS: This retrospective study included 120 AECOPD patients admitted from April 2022 to April 2024. Patients were divided into two groups: the control group received aminophylline, while the study group received doxophylline and ambroxol for 10 days. Clinical efficacy, pulmonary function (FEV1, FVC, FEV1%, FEV1/FVC), inflammatory markers (CRP, PCT, WBC, NEUT%), blood gas parameters (PaO2, PaCO2), CAT and CCQ scores and adverse events were compared pre- and post-treatment.
RESULTS: Post-treatment, both groups showed significant improvements in FEV1, FVC, FEV1% and FEV1/FVC compared to baseline (P<0.05), with the study group demonstrating superior outcomes (P<0.05). Inflammatory markers (CRP, PCT, WBC, NEUT%) decreased significantly in both groups, with greater reductions in the study group (P<0.05). Blood gas parameters (PaO2, PaCO2) improved in both groups (P<0.05), with more pronounced improvements in the study group (P<0.05). CAT and CCQ scores declined in both groups, but more substantially in the study group (P<0.05). No significant difference in adverse events was observed (P>0.05).
CONCLUSION: Doxophylline-ambroxol combination therapy is more effective than aminophylline in improving pulmonary function and reducing inflammation in AECOPD, with equivalent safety.
OBJECTIVES: To compare the clinical efficacy and safety of the combination therapy of Doxophylline ambroxol and Aminophylline monotherapy in the treatment of AECOPD.
METHODS: This retrospective study included 120 AECOPD patients admitted from April 2022 to April 2024. Patients were divided into two groups: the control group received aminophylline, while the study group received doxophylline and ambroxol for 10 days. Clinical efficacy, pulmonary function (FEV1, FVC, FEV1%, FEV1/FVC), inflammatory markers (CRP, PCT, WBC, NEUT%), blood gas parameters (PaO2, PaCO2), CAT and CCQ scores and adverse events were compared pre- and post-treatment.
RESULTS: Post-treatment, both groups showed significant improvements in FEV1, FVC, FEV1% and FEV1/FVC compared to baseline (P<0.05), with the study group demonstrating superior outcomes (P<0.05). Inflammatory markers (CRP, PCT, WBC, NEUT%) decreased significantly in both groups, with greater reductions in the study group (P<0.05). Blood gas parameters (PaO2, PaCO2) improved in both groups (P<0.05), with more pronounced improvements in the study group (P<0.05). CAT and CCQ scores declined in both groups, but more substantially in the study group (P<0.05). No significant difference in adverse events was observed (P>0.05).
CONCLUSION: Doxophylline-ambroxol combination therapy is more effective than aminophylline in improving pulmonary function and reducing inflammation in AECOPD, with equivalent safety.